Boehringer's Ofev wins green light in Europe; Wales grants access to Ariad's Iclusig;

> SCIO Health Analytics has picked up Data Intelligence, a business intelligence and analytics provider to the pharma industry. News

> A panel from the U.K.'s Prescription Medicines Code of Practice Authority (PMCPA) has ruled out a complaint from a pharmacist that the artwork image for Boehringer Ingelheim's COPD drug Striverdi is misleading. More

> Boehringer Ingelheim's Ofev has won European approval as a treatment for idiopathic pulmonary fibrosis. Report

> Wales is providing access to Ariad Pharmaceutical's ($ARIA) Iclusig on its National Health Service. More

> BMG Pharma has signed an exclusive distribution agreement with Ferrer Internacional, granting it the rights to promote, sell and market its GelX for the Middle East, Eastern Europe, Russia and North Africa. Release

And Finally... The FDA has clarified the lines between wellness devices and regulated medical devices. More

Suggested Articles

Cardiac risks associated with roxadustat are comparable to placebo in nondialysis patients and to Amgen's standard, Epogen, in those on dialysis.

Pfizer and Merck KGaA's immuno-oncology agent Bavencio failed another gastric cancer study, this time as a maintenance treatment after chemotherapy.

A jury ordered Biogen to pay nearly $6 million to a former sales manager who reported a colleague's misconduct and got fired a few months later.